SOURCE: SNN Incorporated

SNN Incorporated

October 09, 2015 08:30 ET

StockNewsNow.com Publishes New SNNLive Video Interview With Delcath Systems, Inc.

LOS ANGELES, CA--(Marketwired - October 09, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Jennifer K. Simpson, President and CEO of Delcath Systems, Inc. (NASDAQ: DCTH), is a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, according to the Company's website (see here: www.Delcath.com). The video interview was recorded on Wednesday, September 9th, 2015 On-Location in New York City, NY.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Delcath Systems, Inc. - Specialty Pharmaceutical and Medical Device Company Focused on Primary & Metastatic Liver Cancers

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Delcath Systems, Inc.

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers. Our proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. In April 2012 we obtained authorization to affix a CE Mark to our second-generation system, which is currently marketed in Europe as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In the U.S. the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the U.S. Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the U.S. We have commenced a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC), and expect to initiate a global Phase 3 trial in ocular melanoma (OM) that has metastasized to the liver.

Company description and for more information: www.Delcath.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=DBXHydLZG00

Contact Information